AI Article Synopsis
- The study assesses the safety of antirheumatic drugs for women of childbearing age during pregnancy and breastfeeding through a literature review.
- Cytotoxic drugs can impair fertility, while NSAIDs are safe to use until week 32 of pregnancy; acetaminophen and low to moderate corticosteroids are also considered safe.
- Disease-modifying agents like antimalarials, sulfasalazine, azathioprine, and ciclosporin are compatible with pregnancy, and specific medications are deemed safe for lactating mothers, highlighting the importance of careful planning and monitoring during pregnancy.
Article Abstract
The aim of this study is to determine the safety of commonly prescribed antirheumatic drugs at childbearing age, in pregnancy and lactation, through systematic literature review. Patients who take cytotoxic drugs should be informed of the risks of impared fertility. During pregnancy, non steroidal anti-inflammatory drugs (NSAIDs) can be safely administered until gestational week 32. Acetaminophen and low to moderate doses of corticosteroids are safe. Among, the disease-modifying agents, antimalarial agents, sulfasalazine, azathioprine and ciclosporin are compatible with pregnancy, and can be administered until birth. Paracetamol, prednison, antimalarial agents, sulfasalazine and most NSAIDs can safely be used by lactating mothers. To ensure a favourable outcome for both the mother and the child, the pregnancy should be planned, started during a period of disease stability, monitored closely and treated as needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie/2010061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the Efficacy of Medicinal Plants in Treating Bacterial Vaginosis: A Comprehensive Systematic Review of Interventional Studies.
Iran J Nurs Midwifery Res
November 2024
Faculty of Persian Medicine, Herbal and Traditional Medicines Research Center, Department of Traditional Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Background: Bacterial Vaginosis (BV) is the most prevalent cause of vaginal infection among women. This study aimed to summarize the evidence related to the effectiveness of medicinal plants as an alternative therapy for the management of BV.
Materials And Methods: PubMed, Scopus, Cochrane Library, Web of Science, and Medline PubMed were systematically searched.
Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report.
BMC Neurol
January 2025
Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany.
Background: Due to improved treatment options, more SMA patients reach childbearing age. Currently, limited data on pregnant SMA patients is available, especially in relation to disease-modifying therapies (DMT). This case report helps to elucidate new approaches for future guidelines in the management of pregnancy and SMA.
View Article and Find Full Text PDFNeed for individualized counseling regarding psoriasis systemic therapy in women of childbearing age: analysis of the PsoFem study at the University Medical Center Hamburg.
Int J Womens Dermatol
December 2024
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Article Synopsis
- The study focuses on women of childbearing age (WoCBA) with moderate-to-severe psoriasis, examining their treatment options based on their pregnancy plans.
- It compares two groups: those wishing to conceive (CB+) and those not planning to have more children (CB-), noting that there were no major differences in health-related quality of life but a higher use of certain treatments in the CB+ group.
- Results indicate that discussions about family planning were more frequent among the CB+ group, but overall patient-doctor agreement on treatment decisions was only fair-to-moderate, highlighting areas for improvement in shared decision-making.
Epilepsy-pregnancy registries: An update.
Epilepsia
November 2024
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
This report is the first comprehensive update on the activities of existing epilepsy-pregnancy registries since 2010. The primary aim of these registries, which were initiated by independent international research groups some 25 years ago, has been to assess the risk of major congenital malformations (MCMs) in offspring exposed in utero to different antiseizure medications (ASMs). Progress reports are provided here from the five original registries (the International Registry of Antiepileptic Drugs and Pregnancy EURAP, the North American Antiepileptic Drug Pregnancy Registry, the UK and Ireland Epilepsy and Pregnancy Register, the Kerala Registry of Epilepsy and Pregnancy, and the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs) plus the more recently initiated West China Registry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!